First patients screened for a Ib phase study

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in patients with moderately to severely active ulcerative colitis.

The study aims to evaluate the safety and tolerability of the investigational drug. It is expected that more than 30 patients will be randomized in two treatment groups. As of now, the first patients have been screened. The treatment period will take 12 weeks.

This clinical trial is initiated by an international biotech company which develops solutions for immune-mediated diseases.